A MultIceNTER Phase I Peptide VaCcine Trial for the Treatment of H3-Mutated Gliomas
Status:
Not yet recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
The study "A MultIceNTER Phase I Peptide VaCcine Trial to Exploit NeoePitope-Specific T Cells
for the Treatment of H3K27M-Mutated Gliomas - (INTERCEPT H3)" is a non-controlled,
open-label, single arm, multicenter phase I trial involving patients with gliomas carrying an
H3.1K27M or H3.3K27M mutation.
Phase:
Phase 1
Details
Lead Sponsor:
German Cancer Research Center
Collaborators:
Charite University, Berlin, Germany German Cancer Aid Johannes Gutenberg University Mainz Roche Pharma AG